A Study of PHST001 in Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Advanced Solid Tumors · Ovarian Cancer · Endometrial Cancer · Cholangiocarcinoma · CNS Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Precision NextGen Oncology & Research Center, Beverly Hills, California, United States

  • USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

  • Stanford University School of Medicine, Palo Alto, California, United States

  • Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One, Denver, Colorado, United States

  • Yale Cancer Center, New Haven, Connecticut, United States

  • University of Chicago Medical Center, Chicago, Illinois, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

  • START Center for Cancer Research - Midwest, Grand Rapids, Michigan, United States

  • START Center for Cancer Research - Long Island New York, Lake Success, New York, United States

  • Mount Sinai, New York, New York, United States

  • Duke Cancer Institute, Durham, North Carolina, United States

  • Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee, United States

  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

  • START Center for Cancer Research - Texas, Fort Worth, Texas, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • NEXT Oncology - Dallas, Irving, Texas, United States

  • South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States

  • University of Texas (UT) Health, San Antonio, Texas, United States

  • NEXT Oncology - Virginia, Fairfax, Virginia, United States